Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways

Chem Biol Interact. 2021 Feb 1:335:109368. doi: 10.1016/j.cbi.2021.109368. Epub 2021 Jan 4.

Abstract

Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has featured marked anti-inflammatory effects in murine models of myocardial infarction, renal injury, and neuroinflammation. Yet, its potential impact on the pathogenesis of inflammatory bowel diseases (IBD) has not been previously investigated. The presented study aimed to explore the prospect of dapagliflozin to mitigate 2,4,6 trinitrobenzene sulfonic acid (TNBS)-induced rat colitis model which recapitulates several features of the human IBD. The molecular mechanisms pertaining to the dynamic balance between autophagy/apoptosis and colon injury were delineated, particularly, AMPK/mTOR, HMGB1/RAGE/NF-κB and Nrf2/HO-1 pathways. The colon tissues were examined using immunoblotting, ELISA, and histopathology. Dapagliflozin (0.1, 1 and 5 mg/kg; p.o.) dose-dependently mitigated colitis severity as manifested by suppression of the disease activity scores, macroscopic damage scores, colon weight/length ratio, histopathologic perturbations, and inflammatory markers. More important, dapagliflozin enhanced colonic autophagy via upregulating Beclin 1 and downregulating p62 SQSTM1 protein expression. In this context, dapagliflozin activated the AMPK/mTOR pathway by increasing the p-AMPK/AMPK and lowering the p-mTOR/mTOR ratios, thereby, favoring autophagy. Moreover, dapagliflozin dampened the colonic apoptosis via lowering the caspase-3 activity, cleaved caspase-3 expression, and Bax/Bcl-2 ratio. Furthermore, dapagliflozin attenuated the HMGB1/RAGE/NF-κB pathway via lowering HMGB1, RAGE, and p-NF-κBp65 protein expression. Regarding oxidative stress, dapagliflozin lowered the oxidative stress markers and augmented the Nrf2/HO-1 pathway. Together, the present study reveals, for the first time, the ameliorative effect of dapagliflozin against experimental colitis via augmenting colonic autophagy and curbing apoptosis through activation of AMPK/mTOR and Nrf2/HO-1 pathways and suppression of HMGB1/RAGE/NF-κB cascade.

Keywords: AMPK; Autophagy; Colitis; Dapagliflozin; HMGB1; Nrf2.

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Animals
  • Apoptosis* / drug effects
  • Autophagy* / drug effects
  • Benzhydryl Compounds* / therapeutic use
  • Colitis, Ulcerative* / chemically induced
  • Colitis, Ulcerative* / drug therapy
  • Colitis, Ulcerative* / pathology
  • Colon / pathology
  • Glucosides* / therapeutic use
  • HMGB1 Protein
  • Heme Oxygenase (Decyclizing) / metabolism
  • Male
  • NF-E2-Related Factor 2
  • NF-kappa B / metabolism
  • Oxidative Stress / drug effects
  • Rats
  • Rats, Wistar
  • Receptor for Advanced Glycation End Products / metabolism
  • Signal Transduction* / drug effects
  • TOR Serine-Threonine Kinases / metabolism
  • Trinitrobenzenesulfonic Acid

Substances

  • Ager protein, rat
  • AMP-Activated Protein Kinases
  • Benzhydryl Compounds
  • dapagliflozin
  • Glucosides
  • Hbp1 protein, rat
  • Heme Oxygenase (Decyclizing)
  • HMGB1 Protein
  • Hmox1 protein, rat
  • mTOR protein, rat
  • NF-kappa B
  • Receptor for Advanced Glycation End Products
  • TOR Serine-Threonine Kinases
  • Trinitrobenzenesulfonic Acid
  • NF-E2-Related Factor 2